Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We report an unusual case of a 40-year-old male patient who experienced painful swelling of the left lower limb that persisted for 1 week. Imaging modalities not only confirmed the diagnosis of acute iliofemoral venous thrombosis and pulmonary embolism (PE), but also an incidental finding of interrupted inferior vena cava (IVC). This congenital anomaly is uncommon but rarely associated with venous thromboembolism (VTE). The azygos continuation was compressed by the descending aorta against the 11 thoracic vertebrae, which was identified as the cause of VTE. He was treated successfully with anticoagulation and compression therapy. The patient was discharged with lifelong oral Rivaroxaban and remained asymptomatic. In the literature, only 9 cases of interrupted IVC-associated PE were identified but none was due to significant venous compression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/15385744231165213 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of personalised delayed anticoagulation for reducing perioperative blood loss in total knee arthroplasty patients: protocol for a randomised controlled trial.
BMJ Open
September 2025
Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Introduction: The management of bleeding and coagulation after total knee arthroplasty (TKA) has long been recognised as a significant challenge for orthopaedic surgeons. Despite the notable success of empirical anticoagulation in preventing venous thromboembolism (VTE) following TKA, the increased risk of postoperative bleeding has also raised extensive concern. Ecchymosis, as one of the most common manifestations indicating postoperative bleeding, holds the potential to indicate the balance of bleeding and hypercoagulation.
View Article and Find Full Text PDFOverall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
N Engl J Med
September 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.
Background: Data on the levels of rivaroxaban-specific anti-factor Xa activity (AFXaA) within three weeks of starting high-dose rivaroxaban therapy in patients with cancer-associated thromboembolism (CAT) is limited. This study aimed to determine initial levels of rivaroxaban-specific AFXaA in patients with CAT to assist with drug monitoring.
Methods: This study included a total of 33 patients from December 2017 through January 2019.